Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.36 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932261 | 0.88 | FLT3 (0.39) | FLT3EPHX2RETDHODHMTOR | |
| SCHEMBL22931770 | 0.85 | FLT3 (0.41) | FLT3EPHX2RETEGFRDHODH | |
| SCHEMBL24755062 | 0.83 | DHODH (0.40) | FLT3EPHX2RETEGFRDHODH | |
| SCHEMBL22931767 | 0.80 | EPHX2 (0.37) | FLT3EPHX2RETDHODH | |
| SCHEMBL22931766 | 0.79 | EPHX2 (0.45) | FLT3EPHX2RETDHODH | |
| SCHEMBL22932335 | 0.79 | EGFR (0.42) | FLT3EPHX2EGFRDHODH | |
| SCHEMBL29420806 | 0.79 | EGFR (0.42) | FLT3EPHX2EGFRDHODH | |
| SCHEMBL22931806 | 0.78 | FLT3 (0.42) | FLT3EPHX2RETDHODH | |
| SCHEMBL22932203 | 0.76 | DHODH (0.40) | FLT3EPHX2EGFRDHODH | |
| SCHEMBL29420796 | 0.76 | DHODH (0.40) | FLT3EPHX2EGFRDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174291-A | 1,2, 4-oxadiazol-5-one derivatives for the treatment of cancer | 巴斯利尔药物国际股份公司 | 2022-03-11 | — | — | CN | claimed |
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARM INT AG (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-114174291-A | 1,2, 4-oxadiazol-5-one derivatives for the treatment of cancer | 巴斯利尔药物国际股份公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021018869-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | OXER1, CBR3, CCNY | FLT3 707/4885EPHX2 755/4885BCDIN3D 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.